

# OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

<https://marketpublishers.com/r/OAA7A9E61386EN.html>

Date: October 2025

Pages: 100

Price: US\$ 3,000.00 (Single User License)

ID: OAA7A9E61386EN

## Abstracts

### Findings & Highlights:

First OX40 Targeted Therapy Approval By 2030

OX40 Targeted Therapies In Clinical Trials: > 10 Therapies

Cancer Dominating OX40 Targeted Therapies Clinical Trials Landscape

OX40 Targeted Therapies Clinical Trials Insight By Company, Country, Indication & Phase

OX40 Targeted Therapies Proprietary Technologies By Company

Competitive Landscape

### Need For OX40/OX40L Targeted Therapies & Why This Report

OX40/OX40L targeted therapies are rapidly becoming the new target for next generation immunomodulation, especially in immune mediated disorders like atopic dermatitis, asthma, and other inflammatory conditions. This report gives an overview of this fast evolving space, where pharmaceutical investment and academia interest are merging to bring forth a vibrant pipeline of contenders.

With several candidates in late stage trials and innovation extending into combination

strategies as well as diagnostic pairing, knowing the landscape and future direction of OX40/OX40L therapies has never been more important. The report is intended to educate industry players, including investors, biotech executives, and clinical researchers, on the evolving potential of this therapeutic axis and the drivers making it happen

### **OX40/OX40L Targeted Therapies Clinical Trials Insight Covered In Report**

Clinical momentum for OX40/OX40L therapies is increasing, with multiple candidates moving through the pipeline. Particular note has been made of trials indicating promising results in inflammatory dermatological diseases, in which patients tend to have limited alternatives and relapsing disease. Significantly, these treatments are also exhibiting potential for durability of response and selective immune modulation, characteristics that set them apart from existing standards of care. Outside of the US, expanded clinical activity in Europe, China, and Australia demonstrates an expanding global interest in these immunotherapies. This geographical expansion indicates broader acceptance and future potential for regulatory paths across global markets.

### **Technology Platforms, Partnerships & Agreements**

One of the innovations noted in this report is the autoRx40 Platform, which is a proprietary therapeutic development engine that targets OX40 and other related immune receptors. The technology combines antibody engineering and molecular design capabilities to quickly develop bispecific and multi-specific antibodies. Its modular nature and modularity of design enable autoRx40 to deliver targeted therapies that are both immune inhibiting and depleting pathogenic immune cells. The use of the technology in the treatment of complex autoimmune diseases is exemplified through candidates HX035 and HX038. The platform reflects a larger movement in the industry towards the development of scalable and flexible therapeutic engines to address the changing clinical needs.

### **Leading Companies Active In R&D On OX40/OX40L Targeted Therapies**

Several drug making giants and biotech disruptors are making bets in the OX40/OX40L therapy arena. Sanofi and Amgen are taking late-stage candidates with blockbuster potential to the finish, while more recent entrants like Astria Therapeutics are showing promising early-stage evidence with innovative engineering improvements. Companies like ImagenBio are also targeting enhanced safety and minimized off-target effects via matured antibody technologies.

These advancements are frequently fostered by joint ventures, strategic alliances, and academic collaborations that drive innovation cycles and facilitate clinical progress. With further development of these therapies, differentiation among patient response, safety profiles, and dosing intervals will be the marker for success in the marketplace.

### **Report Indicating Future Development Of OX40/OX40L Targeted Therapies**

OX40/OX40L therapies are progressing beyond monotherapy to combinations based on disease severity and patient profile. The future will probably witness combined strategies that bring together biologics and precision diagnostics to optimize therapeutic effects. Future contenders are being developed for longer half-life, less immunogenicity, and better patient compliance, making them strong challengers to current treatments. With late-stage data accumulated and regulatory hurdles cleared, these therapies have the potential to set new standards in immune disease therapy. This paper presents the strategic vision to stakeholders interested in learning or investing in the future wave of immunology innovation.

## Contents

### **1. INTRODUCTION TO OX40/OX40L PATHWAY**

- 1.1 Background Of OX40/OX40L Pathway
- 1.2 Significance In Immunotherapy
- 1.3 OX40/OX40L As Disease Biomarkers

### **2. TARGETING THE OX40/OX40L PATHWAY IN THERAPY**

- 2.1 OX40/OX40L Agonism
- 2.2 OX40/OX40L Antagonism
- 2.3 Targeting Approaches & Mechanisms Of Action
  - 2.3.1 Antibodies
  - 2.3.2 Nucleic Acids
  - 2.3.3 Fusion Protein
  - 2.3.4 Small Molecules
  - 2.3.5 Peptides

### **3. INDICATIONS FOR OX40/OX40L TARGETED THERAPIES**

- 3.1 Cancer
  - 3.1.1 Solid Tumors
  - 3.1.2 Hematologic Malignancies
- 3.2 Infectious Diseases
- 3.3 Autoimmune & Inflammatory Diseases
- 3.4 Other Potential Indications

### **4. OX40/OX40L TARGETED COMBINATION THERAPIES**

### **5. GLOBAL OX40/OX40L TARGETED THERAPY CLINICAL TRIALS OVERVIEW**

- 5.1 By Phase
- 5.2 By Indication
- 5.3 By Company

### **6. GLOBAL OX40/OX40L TARGETED THERAPY CLINICAL TRIALS INSIGHT BY COMPANY, COUNTRY, INDICATION & PHASE**

- 6.1 Preclinical
- 6.2 Phase 0
- 6.3 Phase I
- 6.4 Phase I/II
- 6.5 Phase II
- 6.6 Phase II/III
- 6.7 Phase III

## **7. OX40/OX40L TARGETED THERAPY DEVELOPMENT PLATFORMS BY COMPANY**

## **8. GLOBAL OX40/OX40L TARGETED THERAPY MARKET OUTLOOK**

- 8.1 Current Market Overview
- 8.2 Future Prospects

## **9. GLOBAL OX40/OX40L TARGETED THERAPY MARKET DYNAMICS**

- 9.1 Growth Drivers & Opportunities
- 9.2 Challenges & Strategic Solutions

## **10. COMPETITIVE LANDSCAPE**

- 10.1 AbCellera Biologics
- 10.2 Apogee Therapeutics
- 10.3 Amgen
- 10.4 Astria Therapeutics
- 10.5 Bio-Thera
- 10.6 Elpiscience
- 10.7 HiFiBiO Therapeutics
- 10.8 Inhibrx Biosciences
- 10.9 ImagenBio
- 10.10 Kyowa Kirin
- 10.11 Navigator Medicines
- 10.12 Pfizer
- 10.13 Psivant Therapeutics
- 10.14 Sanofi
- 10.15 Shanghai Henlius Biotech

## List Of Tables

### LIST OF TABLES

Table 1-1: OX40/OX40L As Prognostic Biomarker In Diseases

Table 2-1: Challenges Of OX40 Agonism - Risks & Optimizations

Table 4-1: OX40/OX40L Targeting Combination Therapies In Clinical Trials

## List Of Figures

### LIST OF FIGURES

Figure 1-1: OX40/OX40L Pathway

Figure 1-2: OX40 In T Cell Subset Differentiation

Figure 1-3: OX40/OX40L Signaling Pathway In Disease

Figure 2-1: OX40 Agonism - Mechanism Of Action On T Cells

Figure 2-2: OX40 Agonism - Potential For Immunotherapy Across Diseases

Figure 2-3: OX40 Antagonism - Mechanism Of Action

Figure 2-4: Types Of OX40 Targeting Antibodies

Figure 2-5: Nanobodies Targeting OX40 - A Novel Approach

Figure 2-6: Nucleic Acid-Based Therapies Targeting OX40/OX40L

Figure 2-7: Fusion Proteins Targeting OX40/OX40L - Advantages

Figure 2-8: Small Molecules Targeting OX40-OX40L - Mechanism Of Action

Figure 2-9: Bicycle Peptides Targeting OX40 - Mechanism Of Action

Figure 3-1: HexAgon-HN Phase 2/3 (NCT06295731) Study - Initiation & Completion Year

Figure 3-2: BAT-6026-001-CR Phase 1 (NCT05105971) Study - Initiation & Completion Year

Figure 3-3: HFB-301001-01 Phase 1 (NCT05229601) Study - Initiation & Completion Year

Figure 3-4: FT04CARCIK Phase 1/2 (NCT05869279) Study - Initiation & Completion Year

Figure 3-5: LY007C1101 Phase 1 (NCT06364852) Study - Initiation & Completion Year

Figure 3-6: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation & Completion Year

Figure 3-7: ROCKET-ASCEND Phase 3 (NCT05882877) Study - Initiation & Completion Year

Figure 3-8: ROCKET-Outpost Phase 3 (NCT06224192) Study - Initiation & Completion Year

Figure 3-9: RIVER-AD Phase 2/3 (NCT05492578) Study - Initiation & Completion Year

Figure 3-10: HLX51-FIH101 Phase 1 (NCT05788107) Study - Initiation & Completion Year

Figure 5-1: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Phase, 2025 -2026

Figure 5-2: Global- OX40/OX40L Targeted Therapies In Clinical Trials By Indication,

2025 - 2026

Figure 5-3: Global - OX40/OX40L Targeted Therapies In Clinical Trials By Company, 2025 - 2026

Figure 7-1: ADAPTIR Bispecific

Figure 7-2: ADAPTIR - APVO603

Figure 7-3: Genmab - HexaBody

Figure 7-4: Inhibrx - sdAb Features

Figure 7-5: Conventional vs. sdAb Structure

Figure 7-6: INBRX-106 - Features

Figure 8-1: Global OX40/OX40L Targeting Therapy Market - Future Prospects

Figure 9-1: Global OX40/OX40L Targeting Therapy Market - Drivers & Opportunities

Figure 9-2: Global OX40/OX40L Targeting Therapy Market - Challenges & Strategic Solutions

## I would like to order

Product name: OX40 Targeted Therapies Clinical Trials, Therapeutic Approaches, Proprietary Technology Platforms & Market Opportunity Insight 2026

Product link: <https://marketpublishers.com/r/OAA7A9E61386EN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/OAA7A9E61386EN.html>